Sigyn Therapeutics Company Description
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions to treat cancer and infectious disease disorders in the United States.
Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats.
The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.
In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies.
Sigyn Therapeutics, Inc. was founded in 2019 and is based in San Diego, California.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | James Joyce |
Contact Details
Address: 2468 Historic Decatur Rd. San Diego, Delaware 92106 United States | |
| Phone | 619 353 0800 |
| Website | sigyntherapeutics.com |
Stock Details
| Ticker Symbol | SIGY |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US82674U1060 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James A. Joyce Ph.D. | Co-founder, Chairman and Chief Executive Officer Inventor |
| Craig P. Roberts | Co-founder, Chief Technology Officer and Director |
| Gerald DeCiccio C.P.A., M.B.A. | Chief Financial Officer |
| Charlene R. Owen | Director of Operations |
| Dr. Annette Marleau Ph.D. | Chief Scientific Officer |